Perrigo Company plc (NYSE: PRGO) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -12.52 | Insider Own | 1.22% | Shs Outstand | 138.37M | Perf Week | -0.73% |
| Market Cap | 1.88B | Forward P/E | 5.57 | EPS next Y | 2.43 | Insider Trans | 0.00% | Shs Float | 137.77M | Perf Month | -2.87% |
| Enterprise Value | 4.77B | PEG | - | EPS next Q | 0.52 | Inst Own | - | Short Float | 16.38% | Perf Quarter | 32.29% |
| Income | -1.73B | P/S | 0.45 | EPS this Y | 117.71% | Inst Trans | - | Short Ratio | 6.62 | Perf Half Y | 40.52% |
| Sales | 4.14B | P/B | 0.75 | EPS next Y | 9.77% | ROA | -22.80% | Short Interest | 22.56M | Perf YTD | -2.59% |
| Book/sh | 18.18 | P/C | 4.69 | EPS next 5Y | 6.95% | ROE | -55.97% | 52W High | 22.65 -40.13% | Perf Year | -35.83% |
| Cash/sh | 2.89 | P/FCF | 10.80 | EPS past 3/5Y | - | ROIC | 3.27% | 52W Low | 9.23 46.91% | Perf 3Y | -59.92% |
| Dividend Est. | 1.16 (8.55%) | EV/EBITDA | - | Sales past 3/5Y | -1.51% 0.79% | Gross Margin | 33.26% | Volatility | 3.84% 3.87% | Perf 5Y | -68.96% |
| Dividend TTM | 1.16 (8.55%) | EV/Sales | 1.15 | EPS Y/Y TTM | -901.60% | Oper. Margin | 5.19% | ATR (14) | 0.57 | Perf 10Y | -85.05% |
| Dividend Ex-Date | Aug 28, 2026 | Quick Ratio | 1.32 | Sales Y/Y TTM | -5.21% | Profit Margin | -41.85% | RSI (14) | 50.10 | Recom | 2.64 |
| Dividend Gr. 3/5Y | 3.71% 5.21% | Current Ratio | 2.32 | EPS Q/Q | -12.28% | SMA20 | -4.28% | Beta | 0.69 | Target Price | 36.20 |
| Payout | -11.52% | Debt/Eq | 1.35 | Sales Q/Q | -3.12% | SMA50 | 8.26% | Rel Volume | 2.14 | Prev Close | 13.48 |
| Employees | 8,100 | LT Debt/Eq | 1.33 | Earnings | Nov 04 | SMA200 | 10.86% | Avg Volume | 3.22M | Price | 13.56 |
| IPO Date | Dec 17, 1991 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 28.88% 0.72% | Net Debt/EBITDA | -2.36 | Volume | 6,878,264 | Change | 0.59% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Nov-06-25 | Downgrade | JP Morgan | Overweight → Neutral | |
| Nov-06-25 | Reiterated | Canaccord Genuity | Buy | $40 → $20 |
| Oct-27-25 | Reiterated | Jefferies | Hold | $30 → $23 |
| Aug-07-25 | Reiterated | Canaccord Genuity | Buy | $40 |
| Jan-14-25 | Downgrade | Argus | Buy → Hold | |
| Jan-06-25 | Downgrade | Piper Sandler | Overweight → Neutral | |
| Sep-23-24 | Downgrade | Jefferies | Buy → Hold | $30 |
| Jun-13-24 | Reiterated | Piper Sandler | Overweight | $39 → $36 |
| Apr-08-24 | Reiterated | Piper Sandler | Overweight | $37 → $39 |
| Nov-17-23 | Initiated | Piper Sandler | $37 |
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,145 | 4,253 | 4,373 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,766 | 2,759 | 2,831 | — | — | — | — | — | — | |
| Gross Profit | 1,379 | 1,495 | 1,543 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 333 | 527 | 1,113 | — | — | — | — | — | — | |
| Research and Development | 96 | 95 | 112 | — | — | — | — | — | — | |
| Other Operating Expense | 737 | 529 | 205 | — | — | — | — | — | — | |
| Operating Income | 216 | 343 | 113 | — | — | — | — | — | — | |
| Interest Expense | 163 | 163 | 188 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -1,664 | -1,479 | -6 | — | — | — | — | — | — | |
| Net Income Before Taxes | -1,613 | -1,298 | -81 | — | — | — | — | — | — | |
| Income Taxes | 91 | 104 | 80 | — | — | — | — | — | — | |
| Consolidated Net Income | -1,734 | -1,425 | -172 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -1,702 | -1,402 | -161 | — | — | — | — | — | — | |
| Net Income | -1,734 | -1,425 | -172 | — | — | — | — | — | — | |
| EPS (Recurring) | -12.51 | -10.29 | -1.25 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -12.51 | -10.29 | -1.25 | — | — | — | — | — | — | |
| EPS (Diluted) | -12.52 | -10.29 | -1.25 | — | — | — | — | — | — | |
| EBITDA | -1,224 | -798 | 433 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.45 | 0.45 | 0.81 | — | — | — | — | — | — | |
| Gross Margin | 33.27 | 35.15 | 35.28 | — | — | — | — | — | — | |
| Operating Margin | 5.21 | 8.06 | 2.58 | — | — | — | — | — | — | |
| Net Margin | -41.83 | -33.51 | -3.93 | — | — | — | — | — | — | |
| Shares Outstanding | 139 | 139 | 137 | — | — | — | — | — | — | |
| Market Capitalization | 1,885 | 1,935 | 3,522 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Alford Bradley A | Director | Sep 11 '26 | Option Exercise | 13.66 | 1,263 | 17,253 | 46,728 | Sep 15 |
| Parker Geoffrey M. | Director | Sep 11 '26 | Option Exercise | 13.66 | 1,263 | 17,253 | 34,480 | Sep 15 |
| Ball David | EVP & CBDO | Sep 09 '26 | Option Exercise | 14.34 | 7,701 | 110,432 | 14,448 | Sep 10 |
| Winterman Matthew John | EVP, Supply, Ops, Strategy | Jul 08 '26 | Option Exercise | 10.52 | 17,503 | 184,131 | 15,660 | Jul 09 |
| Khoury Roberto | EVP and President of CSCI | Jul 08 '26 | Option Exercise | 10.52 | 737 | 7,753 | 14,498 | Jul 09 |
| Parker Geoffrey M. | Director | Jun 12 '26 | Option Exercise | 10.99 | 976 | 10,726 | 33,686 | Jun 16 |
| Alford Bradley A | Director | Jun 12 '26 | Option Exercise | 10.99 | 976 | 10,726 | 45,934 | Jun 16 |
| Lockwood-Taylor Patrick | other: Former CEO and director | Jun 05 '26 | Option Exercise | 10.83 | 25,230 | 273,241 | 136,076 | Jun 09 |
| Khoury Roberto | EVP and President of CSCI | Jun 05 '26 | Option Exercise | 10.83 | 17,902 | 193,878 | 17,433 | Jun 08 |
| Willis Robert | EVP & CHRO | Jun 05 '26 | Option Exercise | 10.83 | 3,441 | 37,266 | 52,365 | Jun 08 |
| Lennox Abigail | EVP and CSO | Jun 05 '26 | Option Exercise | 10.83 | 3,823 | 41,403 | 6,603 | Jun 08 |
| Bezerra Eduardo Guarita | EVP & Chief Financial Officer | Jun 05 '26 | Option Exercise | 10.83 | 9,175 | 99,365 | 86,935 | Jun 08 |
| Ball David | EVP & CBDO | Jun 05 '26 | Option Exercise | 10.83 | 2,867 | 31,050 | 7,784 | Jun 08 |
| Atkinson Charles | EVP, General Counsel & Sec. | Jun 05 '26 | Option Exercise | 10.83 | 6,690 | 72,453 | 7,690 | Jun 08 |
| Alford Bradley A | Director | May 14 '26 | Option Exercise | 10.84 | 7,305 | 79,186 | 48,465 | May 15 |